Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Number of operating segments

Number of operating segments at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NumberOfOperatingSegments.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's number of operating segments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's number of operating segments?
BioCryst Pharmaceuticals (BCRX) reported number of operating segments of 1 in Q1 2026.
How has BioCryst Pharmaceuticals's number of operating segments changed year-over-year?
BioCryst Pharmaceuticals's number of operating segments decreased by 0.0% year-over-year, from 1 to 1.
What does number of operating segments mean?
The total count of distinct business components for which the chief operating decision maker regularly reviews financial information to allocate resources and assess performance. This metric provides insight into the organizational complexity and operational focus of the business.